Orca-T therapy boosts survival in elderly with hematologic cancer, while trilaciclib shows promise in triple-negative breast cancer treatment.
Morgan Bayer
Morgan Bayer is an assistant editor for Targeted Oncology and Targeted Therapies in Oncology.
Articles by Morgan Bayer
New guideline favors doublet therapy over triplet for metastatic renal clear cell cancer due to lower toxicity. COSMIC-313 trial shows improved progression-free survival with triplet therapy but significant adverse events.
Allina Health Cancer Institute and Astrin Biosciences are jointly integrating AI to improve the assessment of cancer cells in blood samples, beginning with breast cancer, which faces challenges with mammogram imaging and demands innovative solutions.
A bounty of FDA drug approvals have arrived plus the pivotal role of cytoreductive therapy and more.
In early lines of therapy for relapsed/refractory multiple myeloma, patients receiving cilta-cel demonstrated deep and enduring responses, with overall response rates of 95% and 100% in 2 cohorts.
The ruxolitinib and belumosudil combination demonstrated a 55% overall response rate in GVHD, suggesting synergy between inflammatory pathways. The combination was well-tolerated, delayed the need for other therapies.
This week's Targeted Pulse touches on the latest in cancer news and research updates.
This edition of Targeted Pulse dives into the exciting realm of cutting-edge cancer therapies on the horizon.
Real-world, retrospective data showed that morphologic renal cell carcinoma types and tumor-stages helps to inform recurrence and prognosis.
Fostroxacitabine bralpamide combined with lenvatinib showed acceptable safety and tolerability, while inducing promising efficacy in patients with hepatocellular carcinoma.
At 12 months, patients in the experimental arm showed OS rates of 14.4% compared with 11.1% for patients receiving chemotherapy alone in the phase 3, open-label CheckMate649 study.
Rucaparib showed a significant improvement in progression-free survival compared with docetaxel in metastatic castration- resistant prostate cancer.
The ECHELON-2 study compared brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone chemotherapy with the standard-of-care cyclophosphamide, doxorubicin, vincristine, and prednisone regimen for CD30- positive T-cell lymphoma.
Sarah B. Goldberg, MD, MPH, presented these findings to demonstrate the effective time to use immuno-oncology combination therapy during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow.
Trastuzumab deruxtecan emerges as a superior second-line option for HER2-positive metastatic breast cancer, with a fourfold increase in median progression-free survival vs trastuzumab emtansine, as reported in the DESTINY-Breast03 trial.
An ongoing phase 1a/1b trial is set to evaluate NX-1607-101, an oral small-molecule inhibitor of casitas B-lineage lymphoma B designed to enhance innate and adaptive immune responses and demonstrate antitumor activity and long-term survival in patients with persistent lymphoma including those with diffuse large B-cell lymphoma.
New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.
Among patients with chronic lymphocytic leukemia who progressed after treatment, pirtobrutinib demonstrated a clearance of BTK C481 clones and the development of non-C481 clones.
RMC-6236 was safe and tolerable in patients with mutant solid tumors harboring KRAS G12X mutations across various cancer types.
The need for wider accessibility, equity, and affordability are significant factors to consider for advancement of these BiTE therapies.
In a phase 2 study, frontline bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride was well tolerated in patients with B-cell non-Hodgkin marginal zone lymphoma.
Findings from the phase 1/2 BRUIN trial of show a distinct genetic evolution in patients with B-cell malignancies. However, the baseline BTK mutations did not impede pirtobrutinib’s effectiveness.
The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.
A recent phase 1/2 study revealed promising results, with an estimated 4-month intracranial progression-free survival rate of 70.7% with stereotactic radiosurgery with the combination of nivolumab and ipilimumab.
After results presented at IMS 2023 , further evaluation of strength building and walking in patients with multiple myeloma is underway in the Host-Factor study.
Following PACIFIC-R trial, the ongoing phase 3 LAURA trial is working to evaluate the efficacy and safety of maintenance osimertinib for patients who have unresectable stage III, EGFR-mutated non–small cell lung cancer.
The phase 2 SWOG S1801 trial showed a 42% reduction in 2-year event-free survival for neoadjuvant-adjuvant vs adjuvant-only pembrolizumab for resectable stage IIIB-D/IV melanoma.